Phaseline

Companies › Mestag Therapeutics

Mestag Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MST-0312
Bispecific antibody targeting lymphotoxin beta receptor (LTBR)
LTBRPhase 1Cancer-NeoplasmsDec 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07610941MST-0312Phase 1Cancer-NeoplasmsOncologyDec 2029

Targets

LTBR (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.